uniQure Q1 Earnings Announcement Scheduled
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: seekingalpha
- Earnings Release Date: uniQure is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.88, reflecting a 7.3% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 stands at $5.27 million, representing a substantial 235.7% year-over-year increase; however, the downward revisions in revenue estimates suggest a cautious market outlook on future growth.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and four downward adjustments, while revenue estimates have not been revised upward and have experienced six downward revisions, highlighting analysts' pessimistic expectations for the company's performance.
- Market Reaction: Despite facing financial hurdles, uniQure's stock has risen recently due to regulatory updates on its gene therapy, indicating a market optimism regarding the improved outlook for its AMT-130 asset.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 19.130
Low
33.00
Averages
49.88
High
70.00
Current: 19.130
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Q1 Earnings Announcement Scheduled
- Earnings Release Date: uniQure is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.88, reflecting a 7.3% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 stands at $5.27 million, representing a substantial 235.7% year-over-year increase; however, the downward revisions in revenue estimates suggest a cautious market outlook on future growth.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and four downward adjustments, while revenue estimates have not been revised upward and have experienced six downward revisions, highlighting analysts' pessimistic expectations for the company's performance.
- Market Reaction: Despite facing financial hurdles, uniQure's stock has risen recently due to regulatory updates on its gene therapy, indicating a market optimism regarding the improved outlook for its AMT-130 asset.
See More
uniQure's Gene Therapy Receives Positive Regulatory Developments
- Stock Surge: uniQure (QURE) shares jumped approximately 22% on Thursday, reflecting market optimism regarding positive regulatory developments for its gene therapy candidate AMT-130, particularly amid uncertainty surrounding U.S. approval.
- Application Timeline: The company disclosed plans to submit a marketing authorization application for AMT-130 in the U.K. by Q3 2026, aiming to leverage constructive feedback from regulators to expedite the product's market entry.
- Regulatory Meeting Scheduled: Additionally, uniQure announced that the U.S. FDA has granted a Type B meeting, set for Q2 2026, to discuss the proposed Phase 3 trial decision for AMT-130 and to receive regulatory feedback on a data analysis plan for four-year results expected in Q3 2026.
- CEO's Positive Outlook: CEO Matt Kapusta expressed encouragement from the constructive feedback received from the MHRA, indicating the company's resilience and determination in navigating regulatory challenges as they work towards the submission for AMT-130.
See More
uniQure Advances Huntington's Disease Therapy with Regulatory Plans
- FDA Meeting Scheduled: uniQure plans to meet with the FDA in Q2 2026 to discuss the design of a potential Phase 3 trial in response to the FDA's feedback on insufficient early-stage trial data, thereby paving the way for future drug approval.
- Market Application Plans: The company expects to submit a Marketing Authorization Application (MAA) to the MHRA in Q3 2026, based on three-year early trial data showing a 75% slowing of disease progression at higher doses, significantly enhancing its competitive position in the Huntington's disease treatment market.
- Exploring International Regulatory Pathways: Beyond the U.S. and U.K., uniQure is actively exploring additional regulatory pathways in international markets to expand the market coverage of its treatment options and strengthen its global business footprint.
- Investor Sentiment Shift: uniQure's shares surged 8% on Thursday, reflecting investor optimism regarding progress on its Huntington's disease therapy, particularly as retail trader sentiment shifted from neutral to bullish, indicating strong market support for the therapy.
See More
uniQure Completes Successful Meeting with MHRA, Advancing AMT-130 Application
- Regulatory Meeting Success: uniQure successfully completed a pre-submission meeting with the UK Medicines and Healthcare products Regulatory Agency (MHRA), paving the way for a planned Marketing Authorization Application (MAA) for AMT-130 in Huntington's disease in Q3 2026, indicating positive feedback from regulators on the data package and manufacturing requirements.
- Significant Clinical Data: AMT-130 has shown a statistically significant 75% slowing of disease progression at the high dose compared to a matched external control group in ongoing U.S. and European Phase I/II trials, highlighting the gene therapy's potential in treating Huntington's disease.
- Clear Future Plans: uniQure plans to submit the MAA based on three-year analysis and has scheduled a Type B meeting with the U.S. FDA in Q2 2026 to discuss potential Phase III trial design and statistical analysis plan, further advancing clinical progress.
- Global Registration Pathways: uniQure is actively pursuing additional regulatory pathways outside the U.S. and UK to support potential global registration of AMT-130, with further updates expected in the second half of 2026, demonstrating the company's strategic focus on the global market.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
uniQure Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
- Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.
See More
uniQure Q1 Earnings Announcement Scheduled
- Earnings Release Date: uniQure is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.88, reflecting a 7.3% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 stands at $5.27 million, representing a substantial 235.7% year-over-year increase; however, the downward revisions in revenue estimates suggest a cautious market outlook on future growth.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and four downward adjustments, while revenue estimates have not been revised upward and have experienced six downward revisions, highlighting analysts' pessimistic expectations for the company's performance.
- Market Reaction: Despite facing financial hurdles, uniQure's stock has risen recently due to regulatory updates on its gene therapy, indicating a market optimism regarding the improved outlook for its AMT-130 asset.
See More
uniQure's Gene Therapy Receives Positive Regulatory Developments
- Stock Surge: uniQure (QURE) shares jumped approximately 22% on Thursday, reflecting market optimism regarding positive regulatory developments for its gene therapy candidate AMT-130, particularly amid uncertainty surrounding U.S. approval.
- Application Timeline: The company disclosed plans to submit a marketing authorization application for AMT-130 in the U.K. by Q3 2026, aiming to leverage constructive feedback from regulators to expedite the product's market entry.
- Regulatory Meeting Scheduled: Additionally, uniQure announced that the U.S. FDA has granted a Type B meeting, set for Q2 2026, to discuss the proposed Phase 3 trial decision for AMT-130 and to receive regulatory feedback on a data analysis plan for four-year results expected in Q3 2026.
- CEO's Positive Outlook: CEO Matt Kapusta expressed encouragement from the constructive feedback received from the MHRA, indicating the company's resilience and determination in navigating regulatory challenges as they work towards the submission for AMT-130.
See More
uniQure Advances Huntington's Disease Therapy with Regulatory Plans
- FDA Meeting Scheduled: uniQure plans to meet with the FDA in Q2 2026 to discuss the design of a potential Phase 3 trial in response to the FDA's feedback on insufficient early-stage trial data, thereby paving the way for future drug approval.
- Market Application Plans: The company expects to submit a Marketing Authorization Application (MAA) to the MHRA in Q3 2026, based on three-year early trial data showing a 75% slowing of disease progression at higher doses, significantly enhancing its competitive position in the Huntington's disease treatment market.
- Exploring International Regulatory Pathways: Beyond the U.S. and U.K., uniQure is actively exploring additional regulatory pathways in international markets to expand the market coverage of its treatment options and strengthen its global business footprint.
- Investor Sentiment Shift: uniQure's shares surged 8% on Thursday, reflecting investor optimism regarding progress on its Huntington's disease therapy, particularly as retail trader sentiment shifted from neutral to bullish, indicating strong market support for the therapy.
See More
uniQure Completes Successful Meeting with MHRA, Advancing AMT-130 Application
- Regulatory Meeting Success: uniQure successfully completed a pre-submission meeting with the UK Medicines and Healthcare products Regulatory Agency (MHRA), paving the way for a planned Marketing Authorization Application (MAA) for AMT-130 in Huntington's disease in Q3 2026, indicating positive feedback from regulators on the data package and manufacturing requirements.
- Significant Clinical Data: AMT-130 has shown a statistically significant 75% slowing of disease progression at the high dose compared to a matched external control group in ongoing U.S. and European Phase I/II trials, highlighting the gene therapy's potential in treating Huntington's disease.
- Clear Future Plans: uniQure plans to submit the MAA based on three-year analysis and has scheduled a Type B meeting with the U.S. FDA in Q2 2026 to discuss potential Phase III trial design and statistical analysis plan, further advancing clinical progress.
- Global Registration Pathways: uniQure is actively pursuing additional regulatory pathways outside the U.S. and UK to support potential global registration of AMT-130, with further updates expected in the second half of 2026, demonstrating the company's strategic focus on the global market.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
uniQure Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
- Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.
See More
